John MD's Email Addresses & Phone Numbers

📖 Summary

President & CEO @ As President and CEO is leading Geron, a publicly traded, de-velopment stage biotechnology company after a strategic rea-lignment that has emphasized development of its first-in-class oncology drugs, and divestiture of its embryonic stem cell as-sets. From 2011 to Present (4 years) Menlo Park, CADriver @ From 2010 to 2010 (less than a year) President & CEO @ As President and CEO led Proteolix, a biotechnology company developing proteasome inhibitors (including carfilzomib) for oncology and immunology applications, through a manage-ment realignment and subsequent merger with Onyx Pharma-ceuticals (NASDAQ: ONXX) valued at $856 million. From 2009 to 2010 (1 year) South San Francisco, CACo-Founder & CEO @ As Co-Founder and CEO, led the Company through the ac-quisition, approval and commercialization of two novel endo-crine products (INCRELEX® and SOMATULINE® DEPOT), key partnerships with Genentech and Ipsen S.A., and multiple financing rounds including the IPO in 2004 and subsequent follow-on equity offerings. Tercica merged with Ipsen in the 4th quarter of 2008 in a transaction that valued the company at approximately $660 million. From 2001 to 2008 (7 years) Brisbane, CAFounder & Director @ Developed the business plan and negotiated a joint venture with Corning, Inc., directed site selection and construction of a state-of-the-art, process development and recombinant protein cGMP manufacturing facility in RTP, and as a Director, pro-vided Board oversight for a 450 employee business with multi-ple large pharmaceutical company clients prior to its sale to Akzo Nobel’s Diosynth Division in 2001. From 1993 to 2001 (8 years) Research Triangle Park, NCFounder & CEO @ As Founder and CEO, led the Company through a key part-nership with Genentech, the acquisition, development and ap-proval of an endocrine product, SOMAVERT® (pegvisomant), and the sale of the Company to Pharmacia in 2001. From 1992 to 2001 (9 years) Austin, TXSVP, Medical and Scientific Affairs; Head, North American Clinical Development Center @ Headed up all Phase I-IV clinical development and medical af-fairs activities for pharmaceutical products and devices at NNPI, Novo Nordisk’s largest international subsidiary, and No-vo Nodisk Canada; reported to the CEO of NNPI. From 1991 to 1993 (2 years) Princeton, NJVice President, Clinical Development @ Headed up Phase I-III clinical development for a disease-modifying anti-rheumatic drug, THERAFECTIN®. From 1985 to 1990 (5 years) Greenwich, CTAdjunct Assistant Professor of Medicine @ From 1982 to 1986 (4 years) Philadelphia, PADirector, Medical Research & Services @ Responsible for Phase IIIb and Phase IV clinical programs, medical writing, pharmacovigilence, and medical affairs for McNeil’s marketed products in pain, rheumatology, psychiatry and pancreatic enzyme replacement therapy. Withdrew ZOMAX®, a leading NSAID, from the worldwide market due to serious adverse experiences, and negotiated DESI approval for PARAFON FORTE® with FDA. From 1982 to 1985 (3 years) Spring House, PAAssociate Investigator @ Studied insulin action, the pathophysiology of obesity and type II diabetes, and in vitro, in vivo and clinical effects of pharma-cologic therapies in these disorders; author or co-author of 12 peer-reviewed publications from laboratory of Jerrold Olefsky. From 1980 to 1982 (2 years) Denver, COEndocrinology & Diabetes Fellowship @ University of Colorado From 1980 to 1982 Internal Medicine Residency Program @ Hospital of University of Pennsylvania From 1977 to 1980 MD with Honors @ University of Chicago - The Pritzker School of Medicine From 1973 to 1977 BA, Chemistry @ Earlham College From 1969 to 1973